Complex Regional Pain Syndrome Clinical Trials 2023

Browse 12 Complex Regional Pain Syndrome Medical Studies Across 10 Cities

12 Complex Regional Pain Syndrome Clinics

Reviewed by Michael Gill, B. Sc.
10 Complex Regional Pain Syndrome Clinical Trials Near Me
Top Hospitals for Complex Regional Pain Syndrome Clinical Trials
Image of Stanford University in California.
Stanford University
Palo Alto
2Active Trials
2All Time Trials for Complex Regional Pain Syndrome
2015First Complex Regional Pain Syndrome Trial
Image of Stanford University in California.
Stanford University
Stanford
1Active Trials
2All Time Trials for Complex Regional Pain Syndrome
2016First Complex Regional Pain Syndrome Trial
Image of Fralin Biomedical Research Institute in Virginia.
Fralin Biomedical Research Institute
Roanoke
1Active Trials
1All Time Trials for Complex Regional Pain Syndrome
2023First Complex Regional Pain Syndrome Trial
Image of UCSF Medical Center in California.
UCSF Medical Center
San Francisco
1Active Trials
1All Time Trials for Complex Regional Pain Syndrome
2022First Complex Regional Pain Syndrome Trial
Image of St. Joseph's Healthcare Hamilton King Campus in Ontario.
St. Joseph's Healthcare Hamilton King Campus
Hamilton
1Active Trials
1All Time Trials for Complex Regional Pain Syndrome
2022First Complex Regional Pain Syndrome Trial
Top Cities for Complex Regional Pain Syndrome Clinical Trials
Image of Palo Alto in California.
Palo Alto
2Active Trials
Stanford UniversityTop Active Site
Image of San Francisco in California.
San Francisco
2Active Trials
UCSF Medical CenterTop Active Site
Complex Regional Pain Syndrome Clinical Trials by Phase of Trial
N/A Complex Regional Pain Syndrome Clinical Trials
10Active Complex Regional Pain Syndrome Clinical Trials
10Number of Unique Treatments
8Number of Active Locations
Complex Regional Pain Syndrome Clinical Trials by Age Group
< 65 Complex Regional Pain Syndrome Clinical Trials
1Active Complex Regional Pain Syndrome Clinical Trials
Most Recent Complex Regional Pain Syndrome Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Complex Regional Pain Syndrome Clinical Trials
Treatment Name
Active Complex Regional Pain Syndrome Clinical Trials
All Time Trials for Complex Regional Pain Syndrome
First Recorded Complex Regional Pain Syndrome Trial
Empowered Relief for Youth
1
1
2023
Ketamine and Midazolam
1
1
2023
LIFU - CRPS
1
1
2023
High Frequency rTMS
1
1
2022
Repetitive transcranial magnetic stimulation
1
1
2022

What Are Complex Regional Pain Syndrome Clinical Trials?

Complex Regional Pain Syndrome or CRPS is a condition with prolonged, excess, and out-of-proportion pain and inflammation in an arm or leg. It is developed after surgery, stroke, heart attack, injury, or fracture. Depending on how long a patient suffers from CRPS, it can be divided into three stages acute, subacute, and chronic.

CRPS is a rare medical condition affecting an average of 5.5 people out of every 100,000 per year. People of any age and biological sex can develop complex regional pain syndrome, but it is more common in biological women, especially those aged 40 and around. CRPS is rare in children and the elderly. While treatment for complex regional pain syndrome is possible, especially when started early, its causes are not clearly understood.

Through CRPS clinical trials, medical and health professionals and researchers seek to understand the possible triggers of the condition. Understanding the immune system activation during nerve injury and minimizing the chances of disability in patients of CRPS are also common goals of complex regional pain syndrome clinical trials.

Why Is Complex Regional Pain Syndrome Being Studied Through Clinical Trials?

While complex regional pain syndrome is treatable when diagnosed and addressed early, it can lead to severe symptoms, including disability. Prolonged inflammation and pain in a limb can weaken it, limiting the patient’s mobility, and often leading to tissue wasting. Tissue wasting or atrophy is the deterioration of muscles, bones, and skin when it is not moved enough.

Untreated CRPS significantly impacts a patient’s physical, mental, and quality of life. Therefore, CRPS clinical trials are important for scientists and health professionals to diagnose the condition quickly and more effectively. Clinical trials on complex regional pain syndrome also lead to discoveries of better methods of limiting symptoms and preventing disability.

What Are the Types of Treatments Available for Complex Regional Pain Syndrome?

Early diagnosis is essential for the successful treatment of CRPS. While the treatment plan for each patient is tailored according to their age, lifestyle, and origin of pain, it commonly involves a combination of medication and therapies.

Medications most often prescribed for CRPS treatment include bone-loss, nerve-blocking, high blood pressure medications, OTC pain relievers, anticonvulsants, antidepressants, and corticosteroids. Therapies for CRPS include physical, topical analgesics, heat, biofeedback, stimulation of the spinal cord, and acupuncture.

What Are Some Recent Breakthrough Clinical Trials for Complex Regional Pain Syndrome?

2023: West Virginia School of Medicine, USA, ran CRPS clinical trial to support the idea of mechanism-based treatment rather than symptom-based treatment in patients suffering from the condition. The goal of the clinical trial was to guide the treatment in a more effective and result-oriented way by incorporating mechanism-based drugs. The trial followed the usual practice of tailored treatment plans for the participants and found favorable results for its hypothesis.

2023: A clinical trial by Showa University School of Medicine, Japan, tested the prospect of senso-immonulogic among CRPS patients. The study involved CRPS patients with bone atrophy and utilized enhanced osteoclast differentiation and activation to reverse the damage. While the trials did not produce sufficient results to propose the new method as a cure for bone atrophy, it succeeded in decreasing the bone destruction rate.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: September 9th, 2023

References1 Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011 Oct;152(10):2399-2404. doi: 10.1016/j.pain.2011.07.005. https://pubmed.ncbi.nlm.nih.gov/218560772 Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987 Aug;30(2):191-197. doi: 10.1016/0304-3959(87)91074-8. https://pubmed.ncbi.nlm.nih.gov/36708703 Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipović SR, Hummel FC, Jääskeläinen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schönfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014 Nov;125(11):2150-2206. doi: 10.1016/j.clinph.2014.05.021. Epub 2014 Jun 5. Review. https://pubmed.ncbi.nlm.nih.gov/250344724 Lefaucheur JP, Andre-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipovic SR, Hummel FC, Jaaskelainen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schonfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014 Nov;125(11):2150-2206. doi: 10.1016/j.clinph.2014.05.021. Epub 2014 Jun 5. https://pubmed.ncbi.nlm.nih.gov/250344725 Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, Johnston KL, Pilkonis PA. Development of short forms from the PROMIS sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011 Dec 28;10(1):6-24. doi: 10.1080/15402002.2012.636266. https://pubmed.ncbi.nlm.nih.gov/222507756 Beaton DE, Wright JG, Katz JN; Upper Extremity Collaborative Group. Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am. 2005 May;87(5):1038-46. doi: 10.2106/JBJS.D.02060. https://pubmed.ncbi.nlm.nih.gov/158669677 Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmoller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24. https://pubmed.ncbi.nlm.nih.gov/332436158 Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmöller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24. Review. https://pubmed.ncbi.nlm.nih.gov/332436159 Neblett R, Cohen H, Choi Y, Hartzell MM, Williams M, Mayer TG, Gatchel RJ. The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain. 2013 May;14(5):438-45. doi: 10.1016/j.jpain.2012.11.012. Epub 2013 Mar 13. https://pubmed.ncbi.nlm.nih.gov/2349063410 Lerner AJ, Wassermann EM, Tamir DI. Seizures from transcranial magnetic stimulation 2012-2016: Results of a survey of active laboratories and clinics. Clin Neurophysiol. 2019 Aug;130(8):1409-1416. doi: 10.1016/j.clinph.2019.03.016. Epub 2019 Apr 6. https://pubmed.ncbi.nlm.nih.gov/31104898